Roctavian
Total Payments
$402,883
Transactions
163
Doctors
46
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $402,883 | 163 | 46 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $374,898 | 98 | 93.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,815 | 7 | 4.2% |
| Travel and Lodging | $8,587 | 12 | 2.1% |
| Consulting Fee | $1,300 | 2 | 0.3% |
| Food and Beverage | $1,283 | 44 | 0.3% |
Payments by Type
Research
$374,898
98 transactions
General
$27,985
65 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | BioMarin Pharmaceutical Inc. | $250,334 | 0 |
| Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | BioMarin Pharmaceutical Inc. | $63,471 | 0 |
| Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3) | BioMarin Pharmaceutical Inc. | $30,472 | 0 |
| GENEr8-INH | BioMarin Pharmaceutical Inc. | $18,291 | 2 |
| A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemophilia A Patients with Residual FVIII Levels = 1 IU/dL Receiving Prophylactic FVIII Infusions | BioMarin Pharmaceutical Inc. | $10,525 | 0 |
| A Prospective, Observational Study To Evaluate Seroprevalence and The Rate of Seroconversion of Adeno-Associated Virus Serotypes and Exploratory Vectors in Patients with Hemophilia A [SAAVY] | BioMarin Pharmaceutical Inc. | $1,804 | 0 |
Top Doctors Receiving Payments for Roctavian
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ann Arbor, MI | $365,382 | 94 |
| Maissaa Janbain | Specialist | New Orleans, LA | $11,425 | 3 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $8,107 | 2 |
| , MD | Hematology | Saint Louis, MO | $6,866 | 4 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $4,850 | 1 |
| , MD | Hematology | Columbus, OH | $2,498 | 13 |
| , MD | Hematology & Oncology | Seattle, WA | $1,300 | 2 |
| , MD, MS | Hematology & Oncology | Milwaukee, WI | $1,200 | 1 |
| , M.D | Maternal & Fetal Medicine | Durham, NC | $105.34 | 1 |
| , M.D | Pediatric Hematology-Oncology | Lansing, MI | $105.33 | 1 |
| , MD | Pediatric Hematology-Oncology | Dallas, TX | $93.50 | 1 |
| , MD | Pediatrics | Greenville, SC | $85.23 | 2 |
| , M.D | Pediatric Hematology-Oncology | Cincinnati, OH | $68.34 | 1 |
| , M.D | Pediatrics | Pittsburgh, PA | $44.37 | 1 |
| , M.D | Hematology | Pittsburgh, PA | $44.37 | 1 |
| Susan Kirk | — | Houston, TX | $43.83 | 1 |
| , MD | Pediatric Hematology-Oncology | Orange, CA | $39.75 | 2 |
| , MD | Pediatrics | Orange, CA | $39.75 | 2 |
| , M.D | Pediatric Hematology-Oncology | Orange, CA | $39.75 | 2 |
| , APNP | Hematology & Oncology | Green Bay, WI | $31.94 | 1 |
| , MD | Hematology & Oncology | Chicago, IL | $28.99 | 1 |
| , M.D | Pediatrics | Chicago, IL | $28.99 | 1 |
| , M.D | Pediatric Hematology-Oncology | Chattanooga, TN | $28.41 | 1 |
| , M.D | Pediatric Hematology-Oncology | Chattanooga, TN | $28.41 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chattanooga, TN | $28.41 | 1 |
Ad
Manufacturing Companies
- BioMarin Pharmaceutical Inc. $402,883
Product Information
- Type Drug
- Total Payments $402,883
- Total Doctors 46
- Transactions 163
About Roctavian
Roctavian is a drug associated with $402,883 in payments to 46 healthcare providers, recorded across 163 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2023 to 2023. In 2023, $402,883 was paid across 163 transactions to 46 doctors.
The most common payment nature for Roctavian is "Unspecified" ($374,898, 93.1% of total).
Roctavian is associated with 6 research studies, including "Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients" ($250,334).